K031923

AUG I 1 2003

510(k) Summary

SUBMITTER:

B. Braun Medical Inc. 901 Marcon Boulevard Allentown, PA 18109-9341

(610) 596-2375

Contact: Sheri L. Musgnung, Manager, Regulatory

Affairs

DEVICE NAME:

Ultrasite® Valve

COMMON OR USUAL

NAME:

Needle free Injection Site

DEVICE

CLASSIFICATION:

Class II per Code of Federal Regulations,

Title 21, § 880.5440, Intravascular Administration

Sets, product code FPA

PREDICATE DEVICE:

B. Braun Medical Inc.'s Ultrasite Valve (previously

known as V2 Injection Site (K955585)

DESCRIPTION:

B. Braun Medical's Ultrasite® Valve is intended for aspiration, injection or gravity/pump flow of fluids upon insertion of a male lucr fitting.

The Ultrasite Valve may also be used with power injectors for which the maximum pressure setting is 300 psi. When used with a power injector, the Ultrasite Valve must be secured to other devices with a lucr lock connection; other devices must also be rated for 300 psi. The Ultrasite Valve is designed to aid in the prevention of needlestick injury. For more information of the principles of operation, please refer to Attachment I — Proposed Device Labeling and Instructions for Use.

The Ultrasite Valve is designed to provide needlefree access on I.V. pump sets, gravity sets, and extension sets. The Ultrasite Valve is a needle-free, capless positive displacement valve to be used in place of needles for the administration of fluids. The Ultrasite Valve may be accessed with standard male luer connectors and requires no special accessory devices.

INTENDED USE:

The Ultrasite® Valve is intended for aspiration, injection or gravity/pump flow of fluids upon insertion of a male luer fitting. The Ultrasite Valve may also be used with power injectors for which the maximum pressure setting is 300 psi. When used with a power injector, the Ultrasite Valve must be secured to other devices with a luer lock connection; other devices must also be rated for 300 psi. The Ultrasite Valve is designed to aid in the prevention of needlestick injury.

SUBSTANTIAL EQUIVALENCE:

The subject Ultrasite Valve is similar in materials and design to B. Braun Medical's premarket notification, Ultrasite Valve (previously known as V2 Injection site), K955585. Functional testing was performed to support that there are no new issues of safety or effectiveness raised by the expanded indications for use for power injectors.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 1 1 2003

Ms. Sheri L. Musgnung Regulatory Affairs Manager B. Braun Medical Incorporated 901 Marcon Boulevard Allentown, Pennsylvania 18109

Re: K031923

Trade/Device Name: Ultrasite® Valve

Regulation Number: 880.5440

Regulation Name: Intravascular Administration Set

Regulatory Class: II Product Code: FPA Dated: June 20, 2003 Received: June 23, 2003

Dear Ms. Musgnung:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4618. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours

Susan Runner, DDS, MA

Interim Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices

filtera Cucento/for

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

×031923

Indications for Us	se Statement		Page 1	of1
510(k) Number (if kn	own):			
Device Name:	Ultrasite® Valve			
Indications For Use:				
The Ultrasite® Valve upon insertion of a m injectors for which th injector, the Ultrasite other devices must als prevention of needles	ale luer fitting. The maximum pressure Valve must be secure to be rated for 300 ps	Ultrasite Valve setting is 300 d to other devi	e may also be us psi. When used ces with a luer lo	ed with power with a power ck connection;
	(Division Sign-Off) Division of Anesthes Infection Control, De	ental Devices	Hospital,	
(PLEASE DO NOT VIF NEEDED) Concurrence of CDRI				THER PAGE
Prescription Use (Per 21 CFR 801.109)			er-The-Counter l	Jse